Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2189-2196

  Cummings, Jeffrey ^a,c   Ethell, Brian T ^b   Jardine, Lesley ^a   Burchell, Brian ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Colon cancer; NU ICRF 505; SN 38; UDP glucuronosyltransferases

Indexed keywords

1 NAPHTHOL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A8; ISOENZYME; ISOPROTEIN; NU ICRF 505; PROPOFOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CLINICAL ARTICLE; COLON; COLON CANCER; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GLUCURONIDATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER FUNCTION; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADENOCARCINOMA; ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLON; COLONIC NEOPLASMS; CRICETINAE; DRUG RESISTANCE, NEOPLASM; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HT29 CELLS; HUMANS; TYROSINE;

EID: 33745576138     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Sobrero A, Kerr D, Glimelius B, VanCutsem E, Milano G, Pritchard DM, Rougier P and Aapro M: New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 36: 559-566, 2000.
2. Tomonaga M, Oka M, Narasaki F, Fukuda M, Nakano R, Takatani H, Ikeda K, Terashi K, Matsuo I, Soda H, Cowan KH and Kokno S: The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancer. Jpn J Cancer Res 87: 1263-1270, 1996.
3. Meschini S, Calcabrini A, Monti E, DelBufalo D, Stringaro A, Dolfini E and Arancia G: Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer 87: 615-628, 2000.
4. Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I and Robert J: Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study. Anticancer Res 24: 579-585, 2004.
5. Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF and Jodrell DI: Glucuronidation as a de novo mechanism of drug resistance in colon cancer cells. Clin Cancer Res 6 (suppl): 82, 2000.
6. Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Friedberg TH, Smith G, Wolf H, Ethell B, Burchell B, Smyth JF and Jodrell DI: Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Proc Am Assoc Cancer Res 42: 278, 2001.
7. Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF and Jodrell DI: Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 63: 8443-8450, 2003.
8. Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF and Jodrell DI: Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 67: 31-39, 2004.
9. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL and Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854, 1998.
10. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G and Guillemette C: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62: 608-617, 2002.
11. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47, 2002.
12. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE and Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382-1388, 2004.
13. Mehra R, Murren J, Chung G, Smith B and Psyrri A: Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism. Clin Colorectal Cancer 5: 61-64, 2005.
14. Tukey RH, Strassburg CP and Mackenzie PI: Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62: 446-450, 2002.
15. Mackenzie PI, Walter Bock K, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS and Nebert DW: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15: 677-685, 2005.
16. Strassburg CP, Oldhaffer K, Manns MP and Tukey RH: Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52: 212-220, 1997.
17. Tukey RH and Strassburg CP: Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59: 405-414, 2001.
18. Gregory PA, Lewinsky RH, Gardner-Stephen DA and Mackenzie PI: Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199: 354-363, 2004.
19. Mojarrabi B and Mackenzie PI: Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon. Biochem Biophys Res Commum 247: 704-709, 1998.
20. Mojarrabi B and Mackenzie PI: The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid. Biochem Biophys Res Commum 238: 775-778, 1997.
21. Ethell BT, Beaumont K, Rance DJ and Burchell B: Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions. Drug Metab Dispos 29: 48-53, 2001.
22. Shelby MK, Cherrington NJ, Vansell NR and Klaassen CD: Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31: 326-333, 2003.
23. Sorich MJ, Miners JO, McKinnon RA and Smith PA: Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 65: 301-308, 2004.
24. Grancharov K, Naydenova Z, Lozeva S and Golovinsky E: Natural and synthetic inhibitors of UDP-glucuronosyltransferase. Pharmacol Ther 89: 171-186, 2001.
25. Cummings J, Meikle I, MacPherson JS and Smyth J: Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug sensitive and drug resistant human ovarian cancer cell lines determined by HPLC. Cancer Chemother Pharmacol 37: 103-109, 1995.
26. Cummings J, Meikle I, MacPherson JS and Smyth JF: Characterisation of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505. Anticancer Drug Design 11: 367-382, 1996.
27. Cummings J, Boyd G, Ethell BT, Macpherson JSM, Burchell B, Smyth JF and Jodrell DI: Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 63(4): 607-613, 2002.
28. Ethell BT, Anderson GD, Beaumont K, Rance DJ and Burchell B: A universal radiochemical high-performance liquid chromatographic assay for the determination of UDP-glucuronosyltransferase activity. Anal Biochem 255: 142-147, 1998.
29. Cummings J, MacPherson JS, Meikle I and Smyth JF: Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem Pharmacol 52: 979-990, 1996.
30. Fournel-Gigleux S, Sutherland L, Sabolovic N, Burchell B and Siest G: Stable expression of two human UDP-glucuronosyltransferase cDNAs in V79 cell cultures. Mol Pharmacol 39: 177-183, 1991.
31. Burchell B, Brierley C and Rance D: Specificity of human UDP-glucuroosyltransferases and xenobiotic glucuronidation. Life Sci 57: 1819-1831, 1995.
32. Ethell BT, Ekins S, Wang J and Burchell B: Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos 30: 734-738, 2002.
33. Strassburg CP, Strassburg A, Nguyen N, Li Q, Manns MP and Tukey RH: Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 338(Pt 2): 489-498, 1999.
34. Strassburg CP, Nguyen N, Manns MP and Tukey RH: UDP- glucuronosyltransferase activity in human liver and colon. Gastroenterology 116: 149-160, 1999.
35. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS and Popescu NC: Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11: 357-368, 2001.
36. Cummings J, Macpherson JS, Boyd G, Ethell BT, Burchell B, Smyth JF and Jodrell DI: Novel mechanism of drug resistance to the topoisomerase I (topo I) inhibitor NU/ICRF 505. Proc Am Assoc Cancer Res 41: 844, 2000.
37. Strassburg CP, Vogel A, Kneip S, Tukey RH and Manns MP: Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50: 851-856, 2002.
38. Miners JO, McKinnon RA and Mackenzie PI: Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182: 453-456, 2002.
39. Huang YH, Galijatovic A, Nguyen N, Geske D, Beaton D, Green J, Green M, Peters WH and Tukey RH: Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12: 287-297, 2002.
40. Jinno H, Saeki M, Tanaka-Kagawa T, Hanioka N, Saito Y, Ozawa S, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N and Sawada J: Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. Drug Metab Dispos 31: 528-532, 2003.
41. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H and Blanchard RL: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11: 1226-1236, 2005.
42. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y and Sawada J: Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31: 687-699, 2001.
43. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S and Sawada J: Glucuronidation of 7-ethyl-10- hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31: 108-113, 2003.
44. Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, Mackenzie PI and Fujiwara Y: UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 24: 2893-2896, 2004.
45. Franklin T, Jacobs V, Jones G, Ple P and Bruneau P: Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res 56: 984-987, 1996.
46. Franklin T, Jacobs V, Jones G and Ple P: Human colorectal carcinoma cells in vitro as a means to assess the metabolism of analogs of mycophenolic acid. Drug Metab Dispos 25: 367-370, 1997.
47. Picard N, Ratanasavanh D, Premaud A, Le Meur Y and Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 55: 139-146, 2005.
48. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S and Ritter JK: An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal rote of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 55: 1513-1520, 2005.
49. Strassburg CP, Manns MP and Tukey RH: Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 275: 8719-8726, 1998.
50. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K and Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
51. Ando M, Ando Y, Sekido Y, Shimokata K and Hasegawa Y: Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 95: 591-597, 2002.
52. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD and Sparreboom A: Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44: 854-860, 2004.
53. Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, Ueoka H, Ohnoshi T and Tanimoto M: Establishment of a 7-ethyl-10-hydroxy-camptothecin- resistant small cell lung cancer cell line. Anticancer Res 24: 3911-3916, 2004.